Hoth Therapeutics (NASDAQ: HOTH) CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
Presentation to highlight advancements in Hoth’s clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors NEW YORK, Oct. 7, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company […]
